Wednesday , March 22 2023

[바이오 유망기업]⑨ Utrex reserves the "world-leading company" for the next-generation immunoconjenogen


[이데일리 이미나 기자]
[이데일리 김지섭 기자] "Innovative immunotherapeutic medicine-based technologies will develop cell therapy and antibody therapies, and will become the world leader in immunosuppressive drugs in rapid commercialization."

A spokeswoman for Kwon Byung-on on August 16 met with reporters at the Plaza Hotel in Jung-gu, Seoul.

Utrex is a biotechnology company that develops drugs for enduring diseases like cancer through immunotherapy using the "immune system" that protects viruses and toxins in the human body. The mission statement "Utrex" also revealed the intention to develop new immunotherapeutic drugs such as "ES" (new), "TI" (immunotherapy) and "LEX" (method).

An immunotoxic agent treats cancer cells with a normal immune system or strengthens the weakened immune system in various ways to prevent cancer cells. Compared with traditional anticancer agents or target cancer agents that attack specific cancer cells, they are less resistant to drugs and are safe from side effects such as leukopenia and hair loss. According to GBI Research, the market for immunotherapy is expected to average on average annually – 23.9% from 18 trillion crowns in 2015 to 86 billion crowns in 2022.

◇ Immunology research "Hanwoo" … Acquired original technology for immunotherapy

Kwon Byung-seh, founded in February 2015 by Utilities, is an immunologic authority that has been working on selling kangwoo products. He was Professor of Chemistry and Biology at the University of Ulsan and Head of Immunocytology at the National Cancer Center at Yale University. Kwon said: "An immunological study over the last 40 years has led to the development of differentiated immunotherapy."

In particular, he was first noticed in 1989 when he discovered the receptor "4-1BB" that stimulates the T-cells associated with an immunomodulatory antibody drug. T cells, immune cells, attacks and destroys cancer cells. 4-1BB can selectively activate or reduce the immune system to activate T cells. Utrex is used to separate and cultivate T cells from the blood of cancer patients and then inject them into the patient's body.

(EBViNT Cell) for the treatment of lymphoma, laryngeal cancer, stomach cancer, etc., is a single-phase glioblastoma / malignant tumor that treats ½ phase, non-small cell lung cancer and breast cancer. WTiNT Cell that treats gliomas, etc., is in the first phase. "Aptity Cell will complete its second phase of clinical trials by 2020," he said. "It is intended to receive a license from the US Food and Drug Administration (FDA) in 2022 with the introduction of innovative medicines."

In addition, the treatment of "Chimic Antigen Receptor-Detected T Cells" (CAR-T), which improves the anti-cancer effect by introducing a gene that successfully detects and destroys cancer cells in T cells (CARs). The current CAR-T therapeutic agent has been shown to cause side effects such as cytokine syndrome, which normal cells attack indifferently and cause hypotension and acute kidney damage. However, CAR-T utilities therapy reduced the adverse effects by targeting only malignant cells targeting "HDL-DR", an antigen that manifests itself when normal cells turn into malignant cells. By standardizing the production process and standardizing the product, the cost of medicine, which has reached several hundreds of millions of wines, has been significantly reduced. Other medicines, such as EU101 and EU102, that are active in cancer cells, activating T-cell immune responses are also being developed.

These new development halls are actively seeking technology exports. Kwon said: "Nowadays, there are many technologies, but nowadays it can not be developed." He said: "We will increase our clinical costs through technology exports and work with global pharmaceutical companies to build success stories."

◇ The development of new medicines in the USA, such as planšte … "Global Big Pharma" aspiration

The key priority of the quota is to create a new ground for resistance in the US and in Europe to develop new drugs. In September, we signed a Memorandum of Understanding with the US JGBLI (JG Business Link International) and ABB Anti-Cell to successfully enter the United States. JGBLI will support research and development (R & D) centers in the United States and consult with the Maryland Pharmacy College to validate anticancer drugs. "This is the first step in clinical trials on T-cell therapy in the United States," Quen said. "We will continue to make efforts to license an immune-compromised medication, starting with the VientiCell application."

The KOSDAQ list for clinical funding is also ahead. On 15 December, it adopted a preliminary examination of the Korean exchange and approved the planned amount of EUR 27.6 billion to EUR 36.4 billion. He said: "The purpose of this list is to make governance transparent and to foster business growth," he said. "From 2022 to the year of release of the product and the export of technology, etc. Growth up to 2013 -" We will reach our vision. "

Source link